After Pfizer (PFE) announced an agreement to acquire Metsera (MTSR) for $4.9B upfront and total potential deal value of about $7.3B contingent on hitting various pipeline-related targets, BofA called the latter “perhaps the best positioned SMid-cap obesity name” and contends that the former gains an “impressive obesity portfolio” via the deal. Metsera’s “lead value-driver,” MET-097i, a monthly GLP1 therapy, is likely to enter Phase 3 trials in 2026, which is only modestly behind Amgen’s (AMGN) Mari-Tide, the analyst tells investors. Metsera also brings a long-acting amylin analog, an oral GLP1, an injectable and an oral “platform,” notes the analyst, who has a Neutral rating and $28 price target on Pfizer shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s Strategic Acquisition and Long-term Growth Concerns: A Hold Rating Analysis
- Arvinas downgraded to Neutral from Buy at BofA
- Pfizer’s Strategic Repositioning in the Obesity Market: A Buy Rating Backed by Undervalued Shares and Growth Potential
- Pfizer’s Strategic Acquisition of Metsera: A Cautious Hold Amid Market Positioning and Regulatory Uncertainty
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz